This new set of data challenges the current “CD47 dogma” according to which most CD47 inhibitory effects on anti-tumor immunity rely on SIRPα binding, and considerably increase the relevance of inhibiting TSP-1/CD47 axis in cancer therapy. The gene discussed is CD47; the disease is cancer.